Effects of Sleeve Gastrectomy in Neonatally Streptozotocin-Induced Diabetic Rats by Wang, Yan et al.
Effects of Sleeve Gastrectomy in Neonatally
Streptozotocin-Induced Diabetic Rats
Yan Wang
1*, Lingling Yan
2, Zhendong Jin
1, Xin Xin
1
1Department of Pharmacology, Basic Medical School, Tongji Medical College, Wuhan, Hubei, China, 2Department of Plastic Surgery, Tongji Hospital, Wuhan, Hubei,
China
Abstract
Background: Sleeve gastrectomy (SG) has emerged recently as a stand-alone bariatric procedure to treat morbid obesity
and enhance glucose homeostasis. The aim of the study was to evaluate its effects in neonatally streptozotocin (STZ)-
induced diabetic rats (n-STZ diabetic rats).
Methodology and Principal Findings: To induce diabetes, STZ (90 mg/kg) was administered intraperitoneally to 2-day-old
male pups. When 12 weeks old, diabetic rats were randomized into sleeve operation group (SLG, n=6) and sham operation
group (SOG, n=6). Body weights were monitored weekly, and daily consumption of water and food were followed for eight
consecutive weeks postoperatively. Serum glucose levels were measured periodically at the 4th and 8th week after surgery.
Insulin, ghrelin, glucose-dependent insulinotropic polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1) levels were
assayed at the end of the study. Our data showed that SLG rats exhibited significantly lower body weight gain in addition to
reduced food and water intakes postoperatively compared to their sham-operation counterparts. However, resolution of
diabetes was not observed in our study. Correspondingly, there were no significant differences between SOG rats and SLG
rats in glucose metabolism-associated hormones, including insulin, GIP and GLP-1. In contrast, ghrelin level significantly
decreased (P,0.01) in SLG group (58.0163.75 pg/ml) after SG surgery compared to SOG group (76.3663.51 pg/ml).
Conclusions: These observations strongly suggest that SG is effective in controlling body weight. However, SG did not
achieve resolution or improvement of diabetes in n-STZ diabetic rats.
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Introduction
Sleeve gastrectomy (SG) is one of the restrictive surgical
procedures applied for treating morbid obesity consisting of
removing the gastric fundus and transforming the stomach into a
narrow gastric tube [1]. This surgical procedure was initially
performed as the first stage for the biliopancreatic diversion/
duodenal switch (BPD/DS) procedure, aiming to reduce operation
risks for super-obese or high-risk patients; however, it has been
validated as a stand-alone bariatric surgery nowadays [2–3].
Moreover, SG has gained increasing popularity with both bariatric
surgeons and patients, mainly because of its relative operative
simplicity and lower risk profile [4–7].
STZ is a chemical substance specifically toxic to pancreatic b
cells. When injected into adult rats, STZ can cause type 1 diabetes
with severely elevated blood glucose levels. However, when STZ is
administered to neonatal rats, the neonates experience acute
hyperglycemia within the first few days. The remaining b cells
soon regenerate to compensate for the destroyed ones, which
makes the rats maintain nearly normoglycaemia during their early
lives [8–9]. Nevertheless, hyperglycemia re-emerges when the
neonatal rats grow into adults, and the rats gradually develop
major features described in type 2 diabetes patients (hyperglyce-
mia, polyphagia, polydipsia, polyuria and abnormal glucose
tolerance) after adulthood [10–12].
Recently, ample evidence demonstrates that SG-induced body
weight loss is accompanied by high rates of improvement or
resolution of type 2 diabetes mellitus [13–14] and other obesity-
associated comorbidities such as dyslipidemia [15], steatohepatitis
[16] and insulin resistance [17]. Apart from promoting excess
weight loss, common explanations for these responses are based on
changes in glucose metabolism-associated hormones including
ghrelin, insulin, and GLP-1 [13–14,18]. Notably, a recent report
demonstrated that while SG led to normalization of glucose levels
in exogenous obesity rats, its hypoglycemic effects in Zucker rats or
Zucker diabetic fatty rats were slight and transient [18]. Therefore,
in order to corroborate the glycemic control effect of SG and
provide further evidence for the application of SG in treating type
2 diabetes in the clinical field, the general aim of this study was to
verify whether SG could ameliorate hyperglycemia in n-STZ
diabetic rats.
We herein evaluated the effects of SG on body weight, intake
and glucose metabolism parameters (insulin, GLP-1, GIP, ghrelin
and blood glycemia levels) in neonatal STZ-induced diabetes
model in rats. Our results showed that SG was effective in
restraining body weight gain and reducing food consumption of
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an effect that lasted. Significantly decreased ghrelin level was also
observed in our study. However, SG could not attenuate
hyperglycemia in n-STZ diabetic rats.
Materials and Methods
Animals
The experiments described in this paper were approved by the
Ethical Committee on Animal Experimentation of Tongji Medical
College, Huazhong University of Science and Technology, China
(Approval ID: 00009543). Healthy SD rats from the Center of
Experimental Animals (Tongji Medical College, Huazhong Univer-
sity of Science and Technology, China) were maintained for breeding
in this research. Male SD pups, aged 48 h62h ,r e c e i v e dS T Z
(Sigma, USA) injection intraperitoneally at a dose of 90 mg/kg body
weight. Normal control pups received vehicle injection of the same
volume. STZ with a dose of 90 mg/kg injected intraperitoneally at 2
days of age is usually applied to induce adult-onset type 2 diabetes in
neonatal rats [19]. STZ was dissolved in citrate buffer (PH=4.5) and
all procedures were performed on ice and in darkness to avoid the
degradation of STZ. All rats were maintained in a controlled
environment with a light/dark cycle of 12 h, a temperature of
2062uC and a humidity of 5062%. Water and normal rodent chow
(60% carbohydrate, 20% protein, 10% vitamin and mineral mix, 5%
fat and 5% cellulose) were given to the rats ad libitum.
Methods
Prior to intervention. When 12 weeks old, rats were selected
for screening by oral glucose test (OGTT). Rats were fasted 12 h,
and glucose was administered orally to the rats at a dose of 2.5 g/
kg body weight. Serum glucose levels of 0 h, 0.5 h, 1 h, 1.5 h and
2 h were measured. Rats with blood glucose level$200 mg/dl at
2 h were considered to be diabetic and later included in the
research. A total of 12 diabetic rats were randomized into sleeve
operation group (SLG, n=6) and sham operation group (SOG,
n=6). Randomly selected normal control rats made up of the
normal control group (NC, n=6).
Day of intervention. Rats were fasted 12 h while water was
available ad libitum before surgery. Rats were anesthetized with an
intraperitoneal injection of 40 mg/kg pentobarbital sodium and
placed supinely with the extremities immobilized. Antibiotic
prophylactic was applied by injecting penicillin intramuscularly at
a dose of 50 mg/kg 30 min prior to the surgery. The abdomen was
shaved and midline incision was made with the length being about
3–4 cm in total. Atraumatic hemostatic forceps were placed along
the greater curvature from the antrum to the fundus. A scalpel was
used todividethe greatercurvaturealongtheatraumatichemostatic
forceps removing approximately 70%–80% of the total stomach.
The remnant stomach was sterilized with iodine and then closed
with 5-0 silk suture by double continuous stitching. Suture line was
examined for integrity and an additional stitch was applied when
necessary. After the gastric tube was rebuilt, the peritoneal cavity
was cleaned with saline and then closed with 3–0 silk suture. For
sham operation, the technique consisted of the same procedure
described above except for the resection of the stomach. Each
animal was given warmed sterile saline subcutaneously after surgery
to avoid dehydration, and allowed to recover spontaneously from
anesthesia. Rats were returned to individual cages to avoid
cannibalism.
Postoperative care. Before resuming oral nutrition, Rats
were injected subcutaneously with 5 ml sterile saline twice within
the first 24 h and 5 ml glucose-saline solution twice a day within
the next 48 h. Thereafter, normal chow was offered to the rats in
small amounts frequently to prevent early dilation of the stomach
for the following 4 consecutive days. Water and chow were given
to the rats ad libitum after the 8th day.
After intervention. Rats were permitted to recover fully
within the first 7 days, and daily consumption of water and food
of each rat was recorded after the 8th day. Body weights
were measured once every week for 7 consecutive weeks
postoperatively.
Biochemical parameters
Blood was drawn from the ophthalmic venous plexus of the rats,
with or without 12 h of fasting (measurement of fasting or fed
glucose levels), in the morning at the 4th and 8th week after
operation. At the end of the study (the 8th week postoperatively),
total blood samples drawn in the fasting state, under cold
conditions, were pooled for the assay of insulin, GIP, GLP-1
and ghrelin levels. They were treated with an inhibitor of
dipeptidyl dipeptidase IV (10 ml/mL blood; Millipore Corpora-
tion, USA) immediately after collection, because dipeptidyl
dipeptidase IV was a peptide in the blood which degraded GLP-
1. Blood samples were centrifuged at 3500 rpm/min for 15 min at
4uC, and the resulting serum samples were stored at 280uC until
analysis. Blood glucose was monitored using colorimetric assay kit
(BioSino Bio-technology and Science Inc, China). Insulin level was
determined by radioimmunoassay (Rat insulin RIA kit, Beijing
North Institute of Biological Technology, China). GIP (Millipore
Corporation, USA), active ghrelin (Millipore Corporation, USA)
and active GLP-1 (Millipore Corporation, USA) levels were
measured using commercial ELISA kits. Intra- and inter-assay
reproducibility of assay kits data was available in Text S1.
Statistical Assays
All values were presented as means6SEM. Blood glucose levels
were analyzed using one-way ANOVA followed by Turkey’s test.
All other data were analyzed for statistical significance by unpaired
student’s test. A P value of less than 0.05 was considered
significant.
Results
All rats survived the surgery and maintained good health
condition throughout the experiment.
Body weight control
Evolution of the average weights of SLG rats and SOG rats
after surgery was shown in Figure. 1A. In the beginning of the
study, the two groups had nearly the same average weights
(345.67613.51 g for SLG rats and 344.17610.44 g for SOG rats).
However, SLG rats showed much less weight gain (P,0.01;
Figure. 1B) postoperatively compared to their sham-operation
counterparts. By the end of the study, body weights of the two
groups (429.1768.84 g for SLG rats and 469.83614.88 g for
SOG rats) differed statistically significant (P,0.05; Figure. 1A).
Daily intakes of water and chow
Daily intakes of water and food were recorded and summarized
into the weekly consumption of water and food. There were
significant differences in food (P,0.05) and water (P,0.01)
consumption between SLG rats and SOG rats throughout the
observation period, as shown in Figure 2.
Biochemical parameters
As shown in Table 1, administration of STZ to neonatal SD
rats resulted in significant hyperglycemia after adulthood. The
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dial glucose levels compared to NC rats (P,0.01). Furthermore,
there was a progressive deterioration of diabetes in n-STZ diabetic
rats. Fasting glucose levels of n-STZ diabetic rats were close to
normal (107.57610.00 mg/dl) at the 4th week after surgery
compared with NC rats (90.4563.60 mg/dl), and increased
significantly at the 8th week postoperatively (117.3064.50 mg/dl
for n-STZ diabetic rats and 95.1462.00 mg/dl for NC rats;
P,0.01). Contrary to what we expected, SG did not ameliorate
hyperglycemia in n-STZ diabetic rats. Fasting and fed glucose
levels of SOG rats and SLG rats, at the 4th and 8th week after SG
intervention, were listed in Table 1. Moreover, as shown in
Table 2, there were no significant differences between SOG rats
and SLG rats with respect to glucose metabolism-associated
hormones, including insulin, GIP and GLP-1. Nevertheless,
ghrelin, a gut hormone which was closely involved in appetite
Figure 1. Effect of SG on body weights of rats. (A) Average weight evolution of rats after SG operation. (B) Body weight gain of rats after SG
operation. All values are based on the initial body weights of rats. Data are presented as means 6SEM (n=6 in each group). * P,0.05 and ** P,0.01
vs. SOG group.
doi:10.1371/journal.pone.0016383.g001
Figure 2. Effect of SG on intakes of rats. (A) Food consumption of rats after SG operation. (B) Water intakes of rats after SG operation. Data are
presented as means 6SEM (n=6 in each group). * P,0.05 and ** P,0.01 vs. SOG group.
doi:10.1371/journal.pone.0016383.g002
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SLG group (58.0163.75 pg/ml) compared to SOG group
(76.3663.51 pg/ml), which might partially explain the reduced
food intakes and restrained body weight gain of SLG rats after SG
intervention.
Discussion
Sleeve gastrectomy (SG) was initially used as the first stage
preceding either duodenal switch or gastric bypass for treating
morbid obesity in high-risk patients [20]. However, it has now
been validated as an isolated bariatric surgery technique to
promote weight loss, which is more rapid and less traumatic [2–
7,21–23]. In the present work, we studied the effects of SG on
body weight, intake and glucose metabolism parameters in n-STZ
diabetic rats. We found that SLG rats manifested significantly
lower body weight gain along with obvious reduction in food
intakes for the 8-week study duration, which provided consistent
evidence for the efficacy of SG in controlling body weight [14–
15,18,24].
Although the role of SG in treating morbid obesity is
undisputed, its mechanisms remain incompletely understood.
Ghrelin is the only gastrointestinal hormone synthesized with a
known orexigenic effect, and it is mainly synthesized in the fundus
of the stomach [18]. During sleeve gastrectomy, the gastric volume
is restricted and the fundus is removed, which significantly
decreases the synthesis of ghrelin. This leads to the lowering of
appetite and reduction of food intake, which may be the main
reason for the sustainable weight loss after SG intervention [24].
Nevertheless, some authors in the literature concluded that the
mechanism for SG to promote weight loss was mainly because this
‘‘food-limiting’’ surgery could enhance gastric motility for solids
together with the hormone changes [25]. In the current study,
significantly decreased ghrelin level was observed in SLG rats
postoperatively, which was in agreement with previous observa-
tions [14,26]. Contradictorily, it was found that ghrelin level was
relatively low in exogenous obesity rats or genetically determined
obesity rats (Zucker rats), and SG did not change [15] or even
increased ghrelin level dramatically [18]. Given the physiological
role of ghrelin, these heterogeneous findings are understandable,
as ghrelin release and gene expression are regulated by the
nutrient flux [27] or the nutritional state [28] of the body. Some
studies reported that ghrelin level was low in the obese, because it
decreased as intake increased [28]. In contrast, ghrelin level was
found to be high in conditions of malnutrition or anorexia nervosa,
which suggested the possible existence of ghrelin resistance [29]. In
the present study, n-STZ diabetic rats developed polyphagia,
polydipsia and polyuria after adulthood [12], and collective
findings demonstrated that significantly increased ghrelin level in
STZ-induced diabetic rats accounted for the diabetic polyphagia
[27,30–31]. These have led us to speculate that in the present
work, SG-induced body weight loss and food intake reduction are
partly, if not totally, due to the ghrelin level change, and
furthermore, have reminded us of the ‘‘hypoinsulinemia’’ in type
1 diabetes and ‘‘hyperinsulinemia and insulin resistance’’ in type 2
diabetes, in which both represent the morbid situation deserving
appropriate therapies to make them go back to normal.
Recently, substantial evidence has emerged demonstrating the
effectiveness of SG in improving or resolving type 2 diabetes [13–
15,32]. However, the mechanism for type 2 diabetes resolution
after SG is yet to be determined. In fact, not just SG, but other
forms of bariatric surgery have been highlighted for their potential
to ameliorate hyperglycemia and tackle type 2 diabetes during
recent years [33–35]. There are two general types of bariatric
surgery: restrictive procedures including gastric banding and SG,
which physically limit the size of the stomach, and gastrointestinal
bypass procedures such as Roux-en-Y gastric bypass (RYGB),
which promote the malabsorption of calories [34]. It was assumed
initially, that the efficacy of bariatric procedures in treating type 2
diabetes was mainly because of their capacities to promote excess
body weight loss [36]. However, some reports later claimed that
glycemic control often occurred long before significant weight loss
in gastrointestinal bypass procedures such as RYGB [37], which
suggested the mechanisms beyond weight loss and calorie
restriction. Nevertheless, despite all the promising results obtained
up to now, enthusiasm must remain guarded, as most clinical
studies were not randomized and thus are suspect with regard to
selection and observational bias [34].
In this research, our results showed that SG failed to attenuate
hyperglycemia in n-STZ diabetic rats. Supporting this finding,
there were no significant changes in the hormones which were
closely associated with glucose metabolism, including insulin,
GLP-1 and GIP. The reason of the discrepancy may lie in the
difference of the model or species. Herein the nature and
characteristics of this n-STZ diabetic rat model needs to be
considered. STZ is a substance specifically toxic to pancreatic b
cells, and the damage STZ causes to b cells leads directly to the
dysfunction of b cells which can not be easily reversed. The n-STZ
diabetic rats have reduced b-cell mass, decreased pancreatic
insulin reserves, and an impaired secretion of insulin to a glucose
stimulus [12]. Therefore, it is possible that in these diabetic rats a
point of ‘‘no return’’ exists in reversing pancreatic failure. Besides,
n-STZ diabetic rats in this study have an uncontrolled disease
duration roughly equivalent to 6 human years, which is relatively
long [1]. In addition, Pereferrer FS [18] investigated the influence
of SG on four experimental models, including non-obesity model,
exogenous obesity caused by excessive calorie intake, genetically
determined obesity(Zucker rats) and genetically determined
obesity and type 2 diabetes mellitus(Zucker diabetic fatty; ZDF
rats). Interestingly, it was found that normalization of weight and
Table 1. Blood glucose levels of rats after SG surgery.
FAG (mg/dl) FEG (mg/dl)
Rat group 4w 8w 4w 8w
NC 90.4563.60 95.1462.00 114.5964.19 119.2867.21
SOG 107.57610.00 117.3064.50
** 199.28610.81
** 212.61611.55
**
SLG 105.9567.43 118.3865.44
** 196.76611.18
** 219.38615.82
**
Data are presented as means 6SEM (n=6 in each group).
**P,0.01 vs. NC group.
FAG: fasting glucose level, FEG: fed glucose level.
doi:10.1371/journal.pone.0016383.t001
Table 2. Effect of SG surgery on hormone levels of rats.
Insulin (mIU/ml) Ghrelin (pg/ml) GIP (pg/ml) GLP-1 (pmol/L)
SOG 29.6664.50 76.3663.51 34.3662.70 4.9260.43
SLG 25.2864.64 58.0163.75
** 34.7163.16 5.7460.61
Data are presented as means6SEM (n=6 in each group).
**P,0.01 vs. SOG group.
GIP: glucose-dependent insulinotropic polypeptide, GLP-1: Glucagon-like
peptide-1.
doi:10.1371/journal.pone.0016383.t002
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model, and effect was slight in Zucker rats or ZDF rats. More
broadly, clinical practices have proved that diabetes resolution
appears to be more pronounced after gastrointestinal bypass
procedures such as RYGB, rather than after the purely restrictive
procedures, and in patients with a milder disease or shorter
preoperative diabetes duration [34,38–39]. These suggest that the
pathogenesis and duration of the disease, the degree of glucose
level, and the surgery adopted are important pre-surgical
predictors of type 2 diabetes outcome following any type of
bariatric surgery.
Taken together, we conclude that SG is effective in controlling
body weight. Meanwhile, we speculate that SG is possibly more
effective to treat mild diabetes with a shorter duration. When
applied to the clinical field, the etiology, pathogenesis and duration
of diabetes should all be considered. Moreover, in order to provide
better guidelines for the application of this bariatric procedure,
further studies are necessary to address putative mechanisms for
SG to treat morbid obesity and diabetes.
Supporting Information
Text S1 Intra- and inter-assay reproducibility of assay kits data.
(DOC)
Acknowledgments
The authors wish to thank Dr. Wei Jie (Department of Pathology,
Guangdong Medical College, China) for his constructive suggestions for
revising the manuscript.
Author Contributions
Conceived and designed the experiments: YW LLY. Performed the
experiments: YW LLY ZDJ XX. Analyzed the data: YW. Contributed
reagents/materials/analysis tools: YW LLY. Wrote the paper: YW.
References
1. Patrikakos P, Toutouzas KG, Perrea D, Menenakos E, Pantopoulou A, et al.
(2009) A surgical rat model of sleeve gastrectomy with staple technique: long-
term weight loss results. Obes Surg 19: 1586–90.
2. Fuks D, Verhaeghe P, Brehant O, Sabbagh C, Dumont F, et al. (2009) Results of
laparoscopic sleeve gastrectomy: a prospective study in 135 patients with morbid
obesity. Surgery 145: 106–13.
3. Sammour T, Hill AG, Singh P, Ranasinghe A, Babor R, et al. (2010)
Laparoscopic sleeve gastrectomy as a single-stage bariatric procedure. Obes
Surg 20(3): 271–5.
4. Frezza EE, Reddy S, Gee LL, Wachtel MS (2009) Complications after sleeve
gastrectomy for morbid obesity. Obes Surg 19: 684–7.
5. Tan JT, Kariyawasam S, Wijeratne T, Chandraratna HS (2010) Diagnosis and
management of gastric leaks after laparoscopic sleeve gastrectomy for morbid
obesity. Obes Surg 20: 403–9.
6. Akkary E, Duffy A, Bell R (2008) Deciphering the sleeve: technique, indications,
efficacy, and safety of sleeve gastrectomy. Obes Surg 18: 1323–9.
7. Goitein D, Goitein O, Feigin A, Zippel D, Papa M (2009) Sleeve gastrectomy:
radiologic patterns after surgery. Surg Endosc 23: 1559–63.
8. Li L, Yi Z, Seno M, Kojima I (2004) Activin A and betacellulin: effect on
regeneration of pancreatic beta-cells in neonatal streptozotocin-treated rats.
Diabetes 53(3): 608–15.
9. Thyssen S, Arany E, Hill DJ (2006) Ontogeny of regeneration of beta-cells in the
neonatal rat after treatment with streptozotocin. Endocrinology 147(5): 2346–56.
10. Hemmings SJ, Spafford D (2000) Neonatal STZ model of type II diabetes
mellitus in the Fischer 344 rat: characteristics and assessment of the status of the
hepatic adrenergic receptors. Int J Biochem Cell Biol 32: 905–19.
11. Chen D, Wang MW (2005) Development and application of rodent models for
type 2 diabetes. Diabetes Obes Metab 7: 307–17.
12. Takada J, Machado MA, Peres SB, Brito LC, Borges-Silva CN, et al. (2007)
Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance
associated with loss of adipose mass. Metabolism 56: 977–84.
13. Lee WJ, Ser KH, Chong K, Lee YC, Chen SC, et al. (2010) Laparoscopic sleeve
gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and
change of insulin secretion. Surgery 147(5): 664–9.
14. Li F, Zhang G, Liang J, Ding X, Cheng Z, et al. (2009) Sleeve gastrectomy
provides a better control of diabetes by decreasing ghrelin in the diabetic Goto-
Kakizaki rats. J Gastrointest Surg 13(12): 2302–8.
15. Lopez PP, Nicholson SE, Burkhardt GE, Johnson RA, Johnson FK (2009)
Development of a sleeve gastrectomy weight loss model in obese Zucker rats.
J Surg Res 157: 243–50.
16. Wang Y, Liu J (2009) Sleeve gastrectomy relieves steatohepatitis in high-fat-diet-
induced obese rats. Obes Surg 19: 921–5.
17. Rizzello M, Abbatini F, Casella G, Alessandri G, Fantini A, et al. (2010) Early
postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg 20:
50–5.
18. Pereferrer FS, Gonza `lez MH, Rovira AF, Blasco SB, Rivas AM, et al. (2008)
Influence of sleeve gastrectomy on several experimental models of obesity:
metabolic and hormonal implications. Obes Surg 18: 97–108.
19. Chakrabarti S, Biswas TK, Seal T, Rokeya B, Ali L, et al. (2005) Antidiabetic
activity of Caesalpinia bonducella F. in chronic type 2 diabetic model in Long-
Evans rats and evaluation of insulin secretagogue property of its fractions on
isolated islets. J Ethnopharmacol 97: 117–22.
20. Saber AA, Elgamal MH, Mcleod MK (2008) Bariatric surgery: the past, present,
and future. Obes Surg 18: 121–8.
21. Sabbagh C, Verhaeghe P, Dhahri A, Brehant O, Fuks D, et al. (2010) Two-year
results on morbidity, weight loss and quality of life of sleeve gastrectomy as first
Procedure, sleeve gastrectomy after failure of gastric banding and gastric
banding. Obes Surg 20: 679–84.
22. Deitel M, Crosby RD, Gagner M (2008) The first international consensus
summit for sleeve gastrectomy (SG), New York city, october 25-27, 2007. Obes
Surg 18(5): 487–96.
23. Bohdjalian A, Langer FB, Shakeri-Leidenmu ¨hler S, Gfrerer L, Ludvik B, et al.
(2010) Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year
results for weight loss and ghrelin. Obes Surg 20(5): 535–40.
24. de Bona Castelan J, Bettiol J, d’Acampora AJ, Castelan JV, de Souza JC, et al.
(2007) Sleeve gastrectomy model in Wistar rats. Obes Surg 17: 957–61.
25. Melissas J, Daskalakis M, Koukouraki S, Askoxylakis I, Metaxari M, et al. (2008)
Sleeve gastrectomy-a ‘‘food limiting’’ operation. Obes Surg 18: 1251–6.
26. Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, et al.
(2005) Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels.
Obes Surg 15: 1024–9.
27. Gelling RW, Overduin J, Morrison CD, Morton GJ, Frayo RS, et al. (2004)
Effect of uncontrolled diabetes on plasma ghrelin concentrations and ghrelin-
induced feeding. Endocrinology 145(10): 4575–82.
28. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, et al. (2002) Plasma
ghrelin levels in lean and obese humans and the effect of glucose on ghrelin
secretion. J Clin Endocrinol Metab 87(1): 240–4.
29. Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, et al. (2001) Weight
gain decreases elevated plasma ghrelin concentrations of patients with anorexia
nervosa. Eur J Endocrinol 145(5): 669–73.
30. Ishii S, Kamegai J, Tamura H, Shimizu T, Sugihara H, et al. (2002) Role of
ghrelin in streptozotocin-induced diabetic hyperphagia. Endocrinology 143(12):
4934–7.
31. Tsubone T, Masaki T, Katsuragi I, Tanaka K, Kakuma T, et al. (2005) Leptin
downregulates ghrelin levels in streptozotocin-induced diabetic mice.
Am J Physiol Regul Integr Comp Physiol 289(6): R1703–6.
32. Rosenthal R, Li X, Samuel S, Martinez P, Zheng C (2009) Effect of sleeve
gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis 5: 429–34.
33. Abbatini F, Rizzello M, Casella G, Alessandri G, Capoccia D, et al. (2010) Long-
term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable
gastric banding on type 2 diabetes. Surg Endosc 24(5): 1005–10.
34. Goldfine AB, Shoelson SE, Aguirre V (2009) Expansion and contraction:
treating diabetes with bariatric surgery. Nat Med 15: 616–7.
35. Kindel TL, Yoder SM, Seeley RJ, D’Alessio DA, Tso P (2009) Duodenal-jejunal
exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a
GLP-1 receptor-mediated mechanism. J Gastrointest Surg 13(10): 1762–72.
36. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, et al. (1995)
Who would have thought it? An operation proves to be the most effective
therapy for adult-onset diabetes mellitus. Ann Surg 222: 339–50.
37. Herron DM, Tong W (2009) Role of surgery in management of type 2 diabetes.
Mt Sinai J Med 76: 281–93.
38. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, et al. (2004)
Bariatric surgery: a systematic review and meta-analysis. JAMA 292: 1724–37.
39. Vidal J, Ibarzabal A, Nicolau J, Vidov M, Delgado S, et al. (2007) Short-term
effects of sleeve gastrectomy on type 2 diabetes mellitus in severely obese
subjects. Obes Surg 17(8): 1069–74.
Effects of SG in N-STZ Diabetic Rats
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16383